Literature DB >> 12090889

Citywide clonal outbreak of multiresistant Acinetobacter baumannii and Pseudomonas aeruginosa in Brooklyn, NY: the preantibiotic era has returned.

David Landman1, John M Quale, David Mayorga, Adedeyo Adedeji, Kalyani Vangala, Jayshree Ravishankar, Carlos Flores, Steven Brooks.   

Abstract

BACKGROUND: Carbapenems are important agents for treating nosocomial gram-negative infections. Carbapenem-resistant bacteria have become increasingly problematic in certain regions. This study determined the citywide prevalence and molecular epidemiological features of carbapenem-resistant Acinetobacter baumannii and Pseudomonas aeruginosa in Brooklyn, NY.
METHODS: All unique patient isolates of A baumannii and P aeruginosa were collected from 15 Brooklyn hospitals from July 1, 1999, through September 30, 1999. Antibiotic susceptibilities, the genetic relatedness of resistant isolates, and the relationship between antibiotic use and resistance rates were determined.
RESULTS: A total of 419 isolates of A baumannii and 823 isolates of P aeruginosa were collected. For A baumannii, 53% were resistant to meropenem and/or imipenem, and 12% were resistant to all standard antibiotics. Ribotyping revealed that a single clone accounted for 62% of the samples and was isolated from patients at all 15 hospitals. The rate of carbapenem resistance was associated with cephalosporin use at each hospital (P =.004). For P aeruginosa, 24% were resistant to imipenem, 5% to amikacin, and 15% to 29% to other antipseudomonal agents. Ribotyping revealed that 3 clones accounted for nearly half of the isolates and were shared by most hospitals.
CONCLUSIONS: Approximately 400 patients were infected or colonized with carbapenem-resistant A baumannii and P aeruginosa during a 3-month period in 1999. A few strains have spread widely throughout hospitals in this region. The prevalence of resistant A baumannii seems to be correlated with cephalosporin use. Multiresistant hospital-acquired bacteria should be viewed as a serious public health issue rather than an individual hospital's problem. An intensive coordinated effort will be needed to effectively address this problem.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12090889     DOI: 10.1001/archinte.162.13.1515

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  54 in total

1.  Longitudinal epidemiology of multidrug-resistant (MDR) Acinetobacter species in a tertiary care hospital.

Authors:  Ji Hoon Baang; Peter Axelrod; Brooke K Decker; Andrea M Hujer; Georgia Dash; Allan R Truant; Robert A Bonomo; Thomas Fekete
Journal:  Am J Infect Control       Date:  2011-08-11       Impact factor: 2.918

2.  Evaluation of antibiotic combinations against multidrug-resistant Acinetobacter baumannii using the E-test.

Authors:  F A Haddad; K Van Horn; C Carbonaro; M Aguero-Rosenfeld; G P Wormser
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2005-08       Impact factor: 3.267

3.  Occurrence of OXA-58-like carbapenemases in Acinetobacter spp. collected over 10 years in three continents.

Authors:  Juliana Coelho; Neil Woodford; Mariya Afzal-Shah; David Livermore
Journal:  Antimicrob Agents Chemother       Date:  2006-02       Impact factor: 5.191

Review 4.  Acinetobacter pneumonia: a review.

Authors:  Joshua D Hartzell; Andrew S Kim; Mark G Kortepeter; Kimberly A Moran
Journal:  MedGenMed       Date:  2007-07-05

Review 5.  Global challenge of multidrug-resistant Acinetobacter baumannii.

Authors:  Federico Perez; Andrea M Hujer; Kristine M Hujer; Brooke K Decker; Philip N Rather; Robert A Bonomo
Journal:  Antimicrob Agents Chemother       Date:  2007-07-23       Impact factor: 5.191

6.  Optimization of meropenem minimum concentration/MIC ratio to suppress in vitro resistance of Pseudomonas aeruginosa.

Authors:  Vincent H Tam; Amy N Schilling; Shadi Neshat; Keith Poole; David A Melnick; Elizabeth A Coyle
Journal:  Antimicrob Agents Chemother       Date:  2005-12       Impact factor: 5.191

Review 7.  A systematic review and meta-analyses show that carbapenem use and medical devices are the leading risk factors for carbapenem-resistant Pseudomonas aeruginosa.

Authors:  Anne F Voor In 't Holt; Juliëtte A Severin; Emmanuel M E H Lesaffre; Margreet C Vos
Journal:  Antimicrob Agents Chemother       Date:  2014-02-18       Impact factor: 5.191

8.  A focus on intra-abdominal infections.

Authors:  Massimo Sartelli
Journal:  World J Emerg Surg       Date:  2010-03-19       Impact factor: 5.469

9.  Multidrug resistant acinetobacter.

Authors:  Vikas Manchanda; Sinha Sanchaita; Np Singh
Journal:  J Glob Infect Dis       Date:  2010-09

10.  Correlation between antibiotic use and changes in susceptibility patterns of Pseudomonas aeruginosa in a medical-surgical intensive care unit.

Authors:  Hatem Kallel; Fouzia Mahjoubi; Hassen Dammak; Mabrouk Bahloul; Chokri Ben Hamida; Hedi Chelly; Noureddine Rekik; Adnéne Hammami; Mounir Bouaziz
Journal:  Indian J Crit Care Med       Date:  2008-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.